美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Medicus Pharma Ltd.

1.01

-0.0700-6.48%

成交量：148.23万

成交额：158.44万

市值：2,536.53万

市盈率：-0.48

高：1.14

开：1.03

低：1.00

收：1.08

52周最高：8.94

52周最低：1.00

股本：2,511.41万

流通股本：1,857.02万

量比：5.16

换手率：7.98%

股息：- -

股息率：- -

每股收益(TTM):-2.1105

每股收益(LYR):-1.1597

净资产收益率：-2660.81%

总资产收益率：-170.69%

市净率：-27.87

市盈率(LYR):-0.87

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

Medicus Pharma获FDA批准Teverelix®针对高心血管风险晚期前列腺癌患者的IIb期研究可继续进行

BUZZ-削减teverelix特许权使用费后，Medicus Pharma股价上涨

Medicus Pharma Ltd.修订协议未改变授权范围、核心知识产权及双方开发职责

Medicus Pharma Ltd. 宣布修订Lifearc许可协议，优化Teverelix®长期经济与开发前景

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/MDCX"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"MDCX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","market":"US","secType":"STK","nameCN":"Medicus Pharma Ltd.","latestPrice":1.01,"timestamp":1770753930620,"preClose":1.08,"halted":0,"volume":1482258,"delay":0,"changeRate":-0.06481481481481487,"floatShares":18570200,"shares":25114144,"eps":-2.1105,"marketStatus":"交易中","change":-0.07,"latestTime":"02-10 15:05:58 EST","open":1.03,"high":1.14,"low":1,"amount":1584440.7161976,"amplitude":0.12963,"askPrice":1.05,"askSize":3240,"bidPrice":1.01,"bidSize":1217,"shortable":3,"etf":0,"ttmEps":-2.1105,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"listingDate":1731560400000,"exchange":"NASDAQ","adjPreClose":1.08,"preHourTrading":{"tag":"盘前","latestPrice":1.05,"preClose":1.08,"latestTime":"09:29 EST","volume":439587,"amount":500166.4405113,"timestamp":1770733745747,"change":-0.03,"changeRate":-0.027778,"amplitude":0.324074},"postHourTrading":{"tag":"盘后","latestPrice":1.08,"preClose":1.08,"latestTime":"19:23 EST","volume":23,"amount":25.53,"timestamp":1770682990048,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":5.158855},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MDCX\",,,,,undefined,":{"symbol":"MDCX","floatShares":18570200,"roa":"-170.69%","roe":"-2660.81%","lyrEps":-1.159715,"volumeRatio":5.158855,"shares":25114144,"dividePrice":0,"high":1.14,"amplitude":0.12963,"preClose":1.08,"low":1,"week52Low":1,"pbRate":"-27.87","week52High":8.94,"institutionHeld":0,"latestPrice":1.01,"committee":-0.453893,"eps":-2.1105,"divideRate":0,"volume":1482258,"delay":0,"ttmEps":-2.1105,"open":1.03,"prevYearClose":1.53,"prevWeekClose":1.11,"prevMonthClose":1.19,"prevQuarterClose":1.53,"fiveDayClose":1.2,"twentyDayClose":1.46,"sixtyDayClose":2.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MDCX\",params:#limit:5,,,undefined,":[{"date":"2025-11-14","symbol":"MDCX","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1763154000000,"name":null,"time":"盘后","dateTimestamp":1763096400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MDCX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MDCX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1744779600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MDCX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MDCX","date":"2026-02-09","current":-0.497133,"percent":0.991304,"low":-3.23298,"twenty":-2.861786,"median":-2.048051,"eighty":-1.018593,"high":-0.765701,"avg":-1.917502,"sd":0.855443,"marketCap":28360481},"quantilePoints":[{"date":"2025-08-29","current":-2.084531,"twenty":-2.272139,"median":-2.126221,"eighty":-2.109545,"marketCap":35632532},{"date":"2025-09-05","current":-1.907346,"twenty":-2.205434,"median":-2.115799,"eighty":-2.053263,"marketCap":32603766},{"date":"2025-09-12","current":-2.345097,"twenty":-2.211687,"median":-2.12101,"eighty":-2.053263,"marketCap":40086598},{"date":"2025-09-19","current":-2.532705,"twenty":-2.511859,"median":-2.178335,"eighty":-2.080362,"marketCap":43293526},{"date":"2025-09-26","current":-2.817408,"twenty":-2.759151,"median":-2.287772,"eighty":-2.103292,"marketCap":48160186},{"date":"2025-10-03","current":-3.005474,"twenty":-2.869667,"median":-2.511859,"eighty":-2.115799,"marketCap":51374941},{"date":"2025-10-10","current":-3.005474,"twenty":-2.994879,"median":-2.558762,"eighty":-2.122052,"marketCap":51374941},{"date":"2025-10-17","current":-2.885734,"twenty":-2.976858,"median":-2.720313,"eighty":-2.151236,"marketCap":49328130},{"date":"2025-10-24","current":-2.909682,"twenty":-2.974342,"median":-2.774974,"eighty":-2.174166,"marketCap":49737492},{"date":"2025-10-31","current":-2.957578,"twenty":-2.974342,"median":-2.817408,"eighty":-2.178335,"marketCap":50556216},{"date":"2025-11-07","current":-2.897708,"twenty":-2.962368,"median":-2.809662,"eighty":-2.228364,"marketCap":49532811},{"date":"2025-11-14","current":-2.706124,"twenty":-2.950394,"median":-2.817408,"eighty":-2.292984,"marketCap":46257915},{"date":"2025-11-21","current":-1.28141,"twenty":-2.950394,"median":-2.789942,"eighty":-2.178335,"marketCap":44939453},{"date":"2025-11-28","current":-1.355609,"twenty":-2.936025,"median":-2.763,"eighty":-2.119968,"marketCap":48464116},{"date":"2025-12-05","current":-1.183077,"twenty":-2.916866,"median":-2.742046,"eighty":-2.04284,"marketCap":42295956},{"date":"2025-12-12","current":-1.201563,"twenty":-2.904892,"median":-2.700137,"eighty":-1.376181,"marketCap":42956830},{"date":"2025-12-19","current":-1.022869,"twenty":-2.897708,"median":-2.63428,"eighty":-1.31987,"marketCap":36568379},{"date":"2025-12-26","current":-0.955088,"twenty":-2.897553,"median":-2.584818,"eighty":-1.266827,"marketCap":34145173},{"date":"2026-01-02","current":-1.074791,"twenty":-2.896932,"median":-2.511859,"eighty":-1.220048,"marketCap":38424640},{"date":"2026-01-09","current":-1.095865,"twenty":-2.885734,"median":-2.329463,"eighty":-1.179996,"marketCap":39178064},{"date":"2026-01-16","current":-0.976444,"twenty":-2.885734,"median":-2.178335,"eighty":-1.123965,"marketCap":34908660},{"date":"2026-01-23","current":-0.94132,"twenty":-2.866576,"median":-2.167912,"eighty":-1.101485,"marketCap":33652952},{"date":"2026-01-30","current":-0.878097,"twenty":-2.861786,"median":-2.115799,"eighty":-1.061072,"marketCap":31392680},{"date":"2026-02-06","current":-0.765701,"twenty":-2.861786,"median":-2.074108,"eighty":-1.022014,"marketCap":27374416},{"date":"2026-02-09","current":-0.793282,"twenty":-2.861786,"median":-2.048051,"eighty":-1.018593,"marketCap":28360481}],"updateTime":1770743953395},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MDCX\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1179126983","title":"Medicus Pharma获FDA批准Teverelix®针对高心血管风险晚期前列腺癌患者的IIb期研究可继续进行","url":"https://stock-news.laohu8.com/highlight/detail?id=1179126983","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179126983?lang=zh_cn&edition=fundamental","pubTime":"2026-02-10 20:30","pubTimestamp":1770726624,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 宣布，其用于治疗伴有高心血管风险的晚期前列腺癌患者的Teverelix® IIb期临床试验，已获得美国食品药品监督管理局（FDA）的“研究可继续进行”许可。这一监管里程碑意味着公司可以按计划推进该临床阶段的研究工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MDCX"],"gpt_icon":0},{"id":"2605994374","title":"BUZZ-削减teverelix特许权使用费后，Medicus Pharma股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2605994374","media":"路透中文","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605994374?lang=zh_cn&edition=fundamental","pubTime":"2026-01-22 21:04","pubTimestamp":1769087043,"startTime":"0","endTime":"0","summary":"BUZZ-削减teverelix特许权使用费后，Medicus Pharma股价上涨1月22日 - ** 药物开发商Medicus Pharma MDCX.O股价盘前上涨12%至1.49美元 ** 该公司表示，在修订与英国研究机构LifeArc的协议后，已将前列腺癌试验药物teverelix的专利使用费从~4%降至2%。** 公司的 teverelix 正在接受晚期前列腺癌和复发性急性尿潴留的测试。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nL4S3YN128:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"1184034229","title":"Medicus Pharma Ltd.修订协议未改变授权范围、核心知识产权及双方开发职责","url":"https://stock-news.laohu8.com/highlight/detail?id=1184034229","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184034229?lang=zh_cn&edition=fundamental","pubTime":"2026-01-22 20:33","pubTimestamp":1769085202,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 近日宣布，其对现有协议的修订并未对原授权协议的范围、基础知识产权归属或合作双方各自的开发责任产生任何实质性改变。此次修订旨在优化合作条款，确保项目推进效率，同时维持原有知识产权框架与开发义务的稳定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0},{"id":"1127677442","title":"Medicus Pharma Ltd. 宣布修订Lifearc许可协议，优化Teverelix®长期经济与开发前景","url":"https://stock-news.laohu8.com/highlight/detail?id=1127677442","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127677442?lang=zh_cn&edition=fundamental","pubTime":"2026-01-22 20:31","pubTimestamp":1769085098,"startTime":"0","endTime":"0","summary":"Medicus Pharma Ltd. 已宣布对其与Lifearc达成的许可协议进行修订。此次修订旨在显著提升其核心产品Teverelix®的长期经济价值和开发潜力。协议的调整预计将为该药物的未来商业化道路带来更有利的条件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDCX","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/MDCX\",params:#limit:6,delay:false,,,undefined,":[]}}